Workflow
GZBL(002424)
icon
Search documents
ST百灵(002424) - 关于对控股子公司提供担保的进展公告
2025-05-05 07:46
证券代码:002424 证券简称:ST 百灵 公告编号:2025-024 贵州百灵企业集团制药股份有限公司 关于对控股子公司提供担保的进展公告 本公司及董事会全体成员保证公告内容真实、准确和完整,公告 不存在虚假记载、误导性陈述或者重大遗漏。 特别提示: 本公司对安顺市大健康医药产业运营有限公司(资产负债率 85.79%)的担保金额为 10,890 万元,占公司最近一期经审计净资产的 比例为 3.42%。请投资者充分关注担保风险。 一、担保事项概述 贵州百灵企业集团制药股份有限公司(以下简称"公司")于2025 年4月3日召开的第六届董事会第十四次会议及2025年4月21日召开的 2025年第一次临时股东大会审议通过了《关于公司为控股子公司安顺 市大健康医药产业运营有限公司申请贷款提供担保的议案》,公司控 股子公司安顺市大健康医药产业运营有限公司(以下简称"大健康医 药")拟向安顺农村商业银行股份有限公司小十字支行(以下简称"农 商行")申请贷款5,000万元,公司将按持股比例55%提供连带责任担 保2,750万元,大健康医药另一股东安顺市医投科技服务有限公司按 持股比例45%提供连带责任担保2,250万元。 ...
ST百灵:积极探索多元化出海路径 2024年扭亏为盈
Zhong Zheng Wang· 2025-04-29 14:29
Core Viewpoint - ST Bailin has successfully turned a profit in 2024, achieving a net profit of 33.62 million yuan, driven by a focus on core business and strategic development initiatives [1][2]. Financial Performance - The company reported total revenue of 3.825 billion yuan for the year [1]. - The net profit attributable to shareholders was 33.62 million yuan, marking a turnaround from previous losses [1]. Strategic Development - ST Bailin is committed to the "removal of ST status and turning losses into profits" as its core task, focusing on its main responsibilities and continuously advancing its "four major platform" development strategy [1]. - The company is enhancing its brand, channels, and R&D to achieve intrinsic growth while also exploring external growth opportunities in traditional Chinese medicine and overseas investments [1]. Product Portfolio and Market Position - The company has established a strong brand "moat," with products covering key areas such as cardiovascular, respiratory, gynecology, and orthopedics, capturing significant market share [1]. - The sales of the compound Yizhi Huanghua spray have exceeded 100 million yuan in major markets, while the flagship product, Yindan Xinnaotong soft capsules, has maintained steady growth with annual sales reaching 1.5 billion yuan [1]. R&D and Innovation - ST Bailin is entering a new phase of drug development, with its key project, Tangning Tongluo tablets, being the first traditional Chinese medicine to enter phase III clinical trials based on human experience [2]. - The company has a robust pipeline with multiple innovative products expected to launch in the next 1-2 years, including BD-77 and Shouling tablets [2]. Global Expansion - The company is actively exploring diverse overseas pathways, accelerating clinical submissions for key products abroad, and leveraging the advantages of the Guangdong-Hong Kong-Macao Greater Bay Area [2]. - Yindan Xinnaotong soft capsules have received drug registration in Brazil and Singapore, with upcoming registrations in Indonesia and Hong Kong [2]. Technological Advancements - AI technology is becoming a crucial factor for pharmaceutical companies to gain competitive advantages, with ST Bailin investing in cutting-edge tech firms [3]. - Collaborations with companies like Chengdu Zeling Bio and Chongqing Haifu Medical are aimed at breakthroughs in AI drug generation and medical technology [3]. Industry Outlook - The Chinese medicine industry is expected to see a turning point with the release of new policies aimed at enhancing quality and promoting high-quality development [3]. - ST Bailin, as a strong innovator with a rich product pipeline, is positioned to benefit from both intrinsic and extrinsic growth strategies in the long term [3].
贵州百灵企业集团制药股份有限公司 关于募集资金年度存放与使用情况的专项报告
Zheng Quan Ri Bao· 2025-04-29 11:11
Group 1 - The company raised a total of RMB 1,480 million by issuing 37 million shares at RMB 40.00 per share, with net proceeds after fees amounting to RMB 1,381 million [2][3][4] - The company has established a dedicated account for managing the raised funds, adhering to regulatory requirements and ensuring investor protection [3][4][5] - As of December 31, 2024, the company has one dedicated fund account for the raised capital [5] Group 2 - The company has utilized excess raised funds for various projects, including the expansion of production facilities, with specific projects like the extraction workshop renovation and the construction of a new building [6][7][8][9] - The company has permanently supplemented its working capital with remaining excess funds from several projects, totaling RMB 7,819 million [11][12] Group 3 - The company reported a net profit of RMB 33.62 million for the year 2024, with the parent company showing a net loss of RMB 15.02 million [28] - The profit distribution plan for 2024 includes no cash dividends, stock bonuses, or capital increases, with retained earnings to be carried forward [26][28][29] Group 4 - The company has undergone changes in accounting policies in accordance with new regulations issued by the Ministry of Finance, effective from January 1, 2024 [31][32][34] - The company has corrected prior accounting errors related to unrecorded sales expenses, amounting to RMB 288.45 million, without affecting current profits [45][46] Group 5 - The company plans to renew its contract with Tianjian Accounting Firm for the 2025 financial audit, citing their experience and compliance with regulatory standards [57][58][59] - The audit fee for the 2024 financial report is set at RMB 2.13 million, subject to approval by the shareholders' meeting [65][66]
ST百灵(002424) - 监事会决议公告
2025-04-29 10:47
3、本次监事会应到监事5人,实到5人。 4、本次监事会由监事会主席周春刚先生主持,公司高级管理人 员列席了本次会议。 5、本次监事会的召集、召开符合《公司法》《公司章程》《监 事会议事规则》及相关法规的规定,会议召开合法有效。 二、监事会会议审议情况 证券代码:002424 证券简称:ST百灵 公告编号:2025-022 贵州百灵企业集团制药股份有限公司 关于第六届监事会第十次会议决议的公告 本公司及监事会全体成员保证公告内容真实、准确和完整,公告 不存在虚假记载、误导性陈述或者重大遗漏。 一、监事会召开情况 1、贵州百灵企业集团制药股份有限公司(以下简称"公司")第 六届监事会第十次会议由公司监事会主席周春刚先生召集,会议通知 于2025年4月18日以专人送达、电子邮件、电话等通讯方式发出。 2、本次监事会于 2025 年 4 月 29 日下午 2:00 在公司三楼会议室 以现场表决方式召开。 表决结果:同意 5 票,反对 0 票,弃权 0 票,获得通过。 三、备查文件 1、经与会监事签字并加盖监事会印章的监事会决议; 本次会议经过充分讨论,会议审议通过了以下议案: 议案一、审议通过《2025 年第一季度报 ...
ST百灵(002424) - 董事会决议公告
2025-04-29 10:46
证券代码:002424 证券简称:ST百灵 公告编号:2025-021 贵州百灵企业集团制药股份有限公司 关于第六届董事会第十六次会议决议的公告 本公司及董事会全体成员保证公告内容真实、准确和完整,公告不存在虚假 记载、误导性陈述或者重大遗漏。 一、会议召开情况 1、贵州百灵企业集团制药股份有限公司(以下简称"公司")第 六届董事会第十六次会议由公司董事长姜伟先生召集,会议通知于 2025年4月18日以专人送达、电子邮件、电话等通讯方式发出。 2、本次董事会于2025年4月29日上午10:00在公司三楼会议室以 现场结合通讯方式召开。 3、本次董事会应参会表决董事共9人,实际参会表决的董事9人。 其中独立董事胡坚、晏国菀、杨明、张洪武以通讯方式进行表决。 4、本次董事会由董事长姜伟先生主持,公司监事和高级管理人 员列席了本次董事会。 经现场及通讯投票表决,会议审议通过了以下议案: 议案一、审议通过《2025年第一季度报告》。 关于《2025年第一季度报告》详见公司指定信息披露媒体《证券 时报》《证券日报》《中国证券报》《上海证券报》及巨潮资讯网 (http://www.cninfo.com.cn)。 该议案中 ...
贵州百灵(002424) - 2025 Q1 - 季度财报
2025-04-29 10:40
Financial Performance - The company's operating revenue for Q1 2025 was ¥760,588,639.34, a decrease of 42.93% compared to ¥1,332,744,270.05 in the same period last year[5] - Net profit attributable to shareholders was ¥24,169,730.06, down 53.25% from ¥51,695,103.14 year-on-year[5] - The net profit after deducting non-recurring gains and losses was ¥1,595,976.79, a significant decline of 96.42% compared to ¥44,605,736.36 in the previous year[5] - Basic and diluted earnings per share were both ¥0.02, reflecting a 50.00% decrease from ¥0.04 in the previous year[5] - Net profit for the current period is ¥24,305,694.00, representing a decline of 52.4% from ¥51,074,838.51 in the previous period[18] - Earnings per share (basic and diluted) is ¥0.02, down from ¥0.04 in the previous period[19] Cash Flow - The net cash flow from operating activities improved to ¥102,624,994.29, a 140.30% increase from a negative cash flow of ¥254,664,208.38 in the same period last year[5] - The net cash flow from operating activities was $102.62 million, a significant improvement compared to a net outflow of $254.66 million in the previous period[21] - Total cash outflow from operating activities amounted to $662.47 million, down from $1.04 billion year-over-year[21] - Cash inflow from financing activities was $619.20 million, compared to $541.07 million in the previous period[21] - Cash outflow for employee compensation was $148.98 million, a decrease from $175.70 million year-over-year[21] - Cash paid for taxes was $78.34 million, down from $114.61 million in the previous period[21] - Cash paid for other operating activities was $252.89 million, reduced from $388.93 million year-over-year[21] Assets and Liabilities - Total assets at the end of the reporting period were ¥7,055,820,136.30, a decrease of 1.11% from ¥7,134,925,658.08 at the end of the previous year[5] - Total current liabilities decreased to ¥3,590,445,962.43 from ¥3,799,824,847.07, a reduction of about 5.5%[14] - Total liabilities amount to ¥3,832,313,151.24, a decrease from ¥3,935,723,314.43 in the previous period[15] - Total non-current assets are valued at ¥3,470,342,343.27, down from ¥3,491,289,386.18, a decrease of approximately 0.6%[14] Research and Development - The company's R&D expenses increased by 168.83% to ¥8,118,990.09, compared to ¥3,020,082.42 in the same period last year, indicating a focus on innovation[8] - Research and development expenses increased to ¥8,118,990.09, up 168.5% from ¥3,020,082.42 in the previous period[18] Shareholder Information - The total number of common shareholders at the end of the reporting period is 80,863[10] - The largest shareholder, Jiang Wei, holds 17.55% of shares, with 245,346,284 shares pledged[10] - The company has a total of 32,588,712 shares held in the repurchase special account, representing 2.33% of total shares[11] - The company has not reported any significant changes in the top 10 shareholders due to margin trading or lending of shares[11] Other Income and Expenses - Other income surged by 672.31% to ¥35,739,844.30, up from ¥4,627,661.00 year-on-year, primarily due to increased government subsidies received by subsidiaries[8] - The company reported a net loss from investment of ¥7,736,280.49, compared to a loss of ¥5,833,183.59 in the previous period[18] - Cash inflow from operating activities totaled ¥765,095,329.13, slightly down from ¥783,207,961.75 last year[20] Accounting and Auditing - The company did not undergo an audit for the first quarter report[22] - The company plans to implement new accounting standards starting in 2025[22]
ST百灵2024年扭亏为盈
Xin Jing Bao· 2025-04-29 07:11
Core Viewpoint - Guizhou BaiLing Pharmaceutical Group Co., Ltd. reported a revenue of 3.825 billion yuan and achieved a net profit of 33.62 million yuan in 2024, marking a turnaround from losses [1] Group 1: Financial Performance - The company achieved a revenue of 3.825 billion yuan in 2024, indicating a significant recovery in financial performance [1] - The net profit for the year was 33.62 million yuan, showcasing a successful turnaround from previous losses [1] Group 2: Product Portfolio and Market Position - Guizhou BaiLing's product lineup includes proprietary traditional Chinese medicine (TCM) products such as Yindan Xinnaotong Soft Capsules and Kesu Ting Syrup, which are key revenue drivers [2] - The company’s main products address various health issues, including cardiovascular diseases and respiratory conditions, with Yindan Xinnaotong Soft Capsules serving over tens of millions of patients and generating annual sales of 1.5 billion yuan [2] - The sales of the compound Yizhi Huanghua Spray have exceeded 100 million yuan in major markets, and the product has applied for TCM variety protection [2] Group 3: Marketing and Distribution Strategy - The company has reformed its marketing model and completed direct sales adjustments in 15 provinces, enhancing its distribution capabilities [3] - A new pharmaceutical logistics park has opened, supporting an annual circulation demand of 5 billion yuan for drugs and medical devices, strengthening the company's supply chain [3] Group 4: Research and Development - Guizhou BaiLing is entering a new phase of drug development, with key projects like Tangning Tongluo Tablets entering phase III clinical trials, marking a significant milestone for TCM [4] - The company has several innovative products in the pipeline, including Huanglian Jiedu Pills, which have completed phase III trials and are nearing market approval [4] - Other projects such as BD-77 and Shaoling Pian are expected to launch in the next 1-2 years, potentially leading to a surge in new product offerings [4]
布局中药出海,贵州百灵2024年度扭亏为盈
Guang Zhou Ri Bao· 2025-04-29 02:42
Core Insights - The traditional Chinese medicine (TCM) industry is undergoing significant adjustments due to policy changes, intensified market competition, and inventory buildup, leading to negative growth in revenue and net profit for the Chinese patent medicine sector in 2024 [1][2] - Guizhou Bailing has established a strong brand presence, with its products covering key therapeutic areas and achieving substantial sales, including over 1 billion yuan in sales for its compound Yizhi Huanghua spray [1][2] - Guizhou Bailing is entering a new phase of drug development, with key projects like Tangning Tongluo tablets advancing to Phase III clinical trials, indicating a faster pace for new drug approvals [1][2][4] Company Performance - In 2024, Guizhou Bailing reported total revenue of 3.825 billion yuan and a net profit of 33.62 million yuan, marking a turnaround from previous losses [4] - The company has received a clean internal control audit report, confirming effective financial reporting controls as of December 31, 2024 [4] Market Outlook - The TCM industry is expected to see a turning point in 2025, supported by new policies aimed at enhancing quality and promoting high-quality development in the TCM sector [2] - Companies with strong innovation capabilities and a rich product pipeline are likely to benefit in the long term as the market stabilizes [2]
ST百灵(002424) - 关于会计政策变更的公告
2025-04-28 19:15
证券代码:002424 证券简称:ST百灵 公告编号:2025-016 贵州百灵企业集团制药股份有限公司 关于会计政策变更的公告 本公司及董事会全体成员保证公告内容真实、准确和完整,公告不存在虚 假记载、误导性陈述或者重大遗漏。 贵州百灵企业集团制药股份有限公司(以下简称"公司")第六届董事会第 十五次会议于2025年4月28日召开,会议审议通过了《关于会计政策变更的议案》, 根据中华人民共和国财政部(以下简称"财政部")的最新规定对公司会计政策 进行相应变更。本次会计政策变更事项无须提交公司股东大会审议,相关会计政 策变更的具体情况如下: 一、本次会计政策变更情况 1、变更的原因 根据2023年10月25日财政部发布的《关于印发<企业会计准则解释第17号> 的通知》(财会【2023】21号)的规定,"关于流动负债与非流动负债的划分"、 "关于供应商融资安排的披露"、"关于售后租回交易的会计处理"的内容,自 2024年1月1日起施行。 根据2024年12月6日财政部发布的《关于印发<企业会计准则解释第18号>的 通知》(财会【2024】24 号)的规定,"关于不属于单项履约义务的保证类质 量保证的会计处理"的 ...
ST百灵(002424) - 关于对会计师事务所2024年度履职情况的评估报告
2025-04-28 19:15
贵州百灵企业集团制药股份有限公司 关于对会计师事务所 2024 年度履职情况的评估报告 贵州百灵企业集团制药股份有限公司(以下简称"公司")聘请天健会计师 事务所(特殊普通合伙)(以下简称"天健会计师事务所")作为公司 2024 年年 报审计及内部控制审计机构。根据财政部、国资委及中国证监会颁布的《国有企 业、上市公司选聘会计师事务所管理办法》《深圳证券交易所上市公司自律监管 指引第 1 号——主板上市公司规范运作》和《公司章程》等要求,公司对天健 会计师事务所 2024 年审计过程中的履职情况进行评估,具体情况如下: 1、基本信息 | 事务所名称 | 天健会计师事务所(特殊普通合伙) | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 成立日期 | 2011 年 月 18 日 组织形式 | 7 | | | 特殊普通合伙 | | | | 注册地址 | 浙江省杭州市西湖区灵隐街道西溪路 128 号 | | | | | | | | 首席合伙人 | 钟建国 上年末合伙人数量 | | | | 241 | 人 | | | 上年末执业人 | ...